The GEMINI-1 Phase 3 trial demonstrated that 53% of patients achieved clear to almost clear skin by Week 4 after a single dose of imsidolimab. How critical is this rapid clearance for the overall treatment and management of GPP?

In GEMINI-2, 100% of patients who received monthly subcutaneous imsidolimab maintained clear to almost clear skin through at least 24 weeks. Can you elaborate on the importance of these maintenance results for long-term disease management?

The trials reported a consistent and favorable safety profile with no treatment-related serious adverse events. How do these safety results impact the potential for imsidolimab to become a preferred treatment option for GPP?

How does the efficacy and safety profile of imsidolimab compare to existing treatments for GPP, and what advantages does it offer over current therapeutic options?

In the GEMINI-2 trial, none of the patients on imsidolimab experienced a flare, whereas 63% of those re-randomized to placebo did. What do these findings suggest about imsidolimab's role in preventing disease recurrence?

The GEMINI-1 trial enrolled patients from diverse global regions. How might these diverse demographics impact the generalizability of the trial results to the broader GPP patient population?

AnaptysBio plans to out-license imsidolimab in 2024. What are the potential benefits and challenges of this strategy for ensuring that the treatment reaches patients who need it most?

Given the results from the GEMINI-1 and GEMINI-2 trials, what future research directions do you anticipate for imsidolimab in GPP and other autoinflammatory diseases? How might these findings influence the development of new treatments for related conditions?